RecruitingPhase 4NCT06055452

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Sponsor

China National Center for Cardiovascular Diseases

Enrollment

120 participants

Start Date

Jan 19, 2024

Study Type

INTERVENTIONAL

Conditions

Hypertension Pre-Heart Failure

Summary

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether SGLT2 inhibitors (a class of medications originally developed for diabetes) can help people with high blood pressure who are at risk of developing heart failure, before heart failure actually develops. **You may be eligible if...** - You are 18 years or older - You have high blood pressure (hypertension) that is currently being treated with medication and is under control (below 140/90 mmHg) - You show early signs of heart stress on tests (enlarged left atrium on echo, elevated filling pressures, or elevated BNP levels) **You may NOT be eligible if...** - You have diabetes - You already have heart failure - You have had a heart attack or acute coronary event in the past 6 months - You have significant kidney disease or are on dialysis - You have had a stroke recently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.